What You Could Have Expected as RNA Came Full Circle in 2026
The 5th Circular & Self-Amplifying RNA Therapeutics Summit was designed for teams actively navigating the transition of circular and self-amplifying RNA from emerging modality to clinical reality.
As excitement gives way to execution, the field now faces a new set of challenges, including enabling durable expression, supporting redosing, aligning RNA design with delivery architecture, and building IND-ready CMC and regulatory strategies.
This highly-focused summit delivered three days of technical depth, strategic clarity, and peer-to-peer discussion, and brought together innovators from CirCode Biomed, Strand Therapeutics, Sail Biomedicines, Replicate Bioscience, HDT Bio, Chimeron Bio, Altamira Therapeutics, CSL, and leading academic institutions. The agenda prioritized real-world lessons, first-in-human data, and platform-level decision-making across discovery, translation, and development.
Attendees enjoyed:
• Clinical and translational data validating circRNA and saRNA durability and safety
• Deep technical sessions on delivery beyond LNPs, immunogenicity engineering, and redosing strategies
• Practical guidance on CMC readiness, IP positioning, and regulatory alignment
• Workshops designed to reduce IND risk and accelerate development timelines
Built for discovery scientists, platform leaders, translational teams, CMC and regulatory experts, and biotech decision-makers, this summit offered the insight and connections required to move next-generation RNA therapeutics forward with confidence.
2026 Event Highlights
Validating Circular & Self-Amplifying RNA in the Clinic
Attendees examined first-in-human and translational data demonstrating durable expression, tissue selectivity, and clinically relevant dosing across emerging RNA programs.
Engineering Durable, Low-Dose RNA Expression
Attendees learned how next-generation RNA architectures and modifications are extending expression from weeks to months while reducing dose and immune burden.
Unlocking Extrahepatic Delivery Beyond LNPs
Attendees discovered novel delivery strategies are enabling redosing and access to previously unreachable tissues using peptide-based and non-LNP systems.
Enabling In Vivo CAR-T and Immune Reprogramming with Circular and Self-Amplifying RNA
Attendees discovered how next-generation RNA modalities are replacing complex ex vivo cell therapies with scalable, injectable in vivo CAR-T solutions.
Attending Companies Included
Partner With Us
Connect with RNA developers actively seeking solutions across discovery, delivery, manufacturing, and regulatory strategy.
Join Biopharma Experts
Network with the scientists and leaders shaping the next wave of RNA medicines beyond linear mRNA.